| Biliary complications following liver transplantation G Kochhar, JM Parungao, IA Hanouneh, MA Parsi World journal of gastroenterology: WJG 19 (19), 2841, 2013 | 274 | 2013 |
| Open: Vedolizumab for ulcerative colitis: treatment outcomes from the VICTORY consortium N Narula, F Peerani, J Meserve, G Kochhar, K Chaudrey, J Hartke, ... Official journal of the American College of Gastroenterology| ACG 113 (9), 1345, 2018 | 144 | 2018 |
| Development and validation of a scoring system to predict outcomes of vedolizumab treatment in patients with Crohn’s disease PS Dulai, BS Boland, S Singh, K Chaudrey, JL Koliani-Pace, G Kochhar, ... Gastroenterology 155 (3), 687-695. e10, 2018 | 124 | 2018 |
| Risk of severe coronavirus disease 2019 in patients with inflammatory bowel disease in the United States: a multicenter research network study S Singh, A Khan, M Chowdhry, M Bilal, GS Kochhar, K Clarke Gastroenterology 159 (4), 1575-1578. e4, 2020 | 117 | 2020 |
| Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period M Iacucci, R Cannatelli, N Labarile, R Mao, R Panaccione, S Danese, ... The lancet Gastroenterology & hepatology 5 (6), 598-606, 2020 | 101 | 2020 |
| Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group B Shen, G Kochhar, U Navaneethan, FA Farraye, DA Schwartz, M Iacucci, ... The lancet Gastroenterology & hepatology 5 (4), 393-405, 2020 | 101 | 2020 |
| Severe disease on endoscopy and steroid use increase the risk for bowel perforation during colonoscopy in inflammatory bowel disease patients U Navaneethan, G Kochhar, H Phull, P GK Venkatesh, FH Remzi, ... Journal of Crohn's and Colitis 6 (4), 470-475, 2012 | 98 | 2012 |
| Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium B Shen, GS Kochhar, R Kariv, X Liu, U Navaneethan, DT Rubin, RK Cross, ... The lancet Gastroenterology & hepatology 6 (10), 826-849, 2021 | 88 | 2021 |
| Retrospective analysis of safety of vedolizumab in patients with inflammatory bowel diseases J Meserve, S Aniwan, JL Koliani-Pace, P Shashi, A Weiss, D Faleck, ... Clinical Gastroenterology and Hepatology 17 (8), 1533-1540. e2, 2019 | 84 | 2019 |
| Capnographic monitoring in routine EGD and colonoscopy with moderate sedation: a prospective, randomized, controlled trial PP Mehta, G Kochhar, M Albeldawi, B Kirsh, M Rizk, B Putka, B John, ... Official journal of the American College of Gastroenterology| ACG 111 (3 …, 2016 | 81 | 2016 |
| Postoperative outcomes in vedolizumab-treated patients undergoing major abdominal operations for inflammatory bowel disease: retrospective multicenter cohort study AL Lightner, KL Mathis, CS Tse, JH Pemberton, B Shen, G Kochhar, ... Inflammatory bowel diseases 24 (4), 871-876, 2018 | 71 | 2018 |
| Old vs new: Risk factors predicting early onset colorectal cancer AR Syed, P Thakkar, ZD Horne, H Abdul-Baki, G Kochhar, K Farah, ... World journal of gastrointestinal oncology 11 (11), 1011, 2019 | 64 | 2019 |
| Role of interventional inflammatory bowel disease in the era of biologic therapy: a position statement from the Global Interventional IBD Group B Shen, G Kochhar, U Navaneethan, X Liu, FA Farraye, Y Gonzalez-Lama, ... Gastrointestinal endoscopy 89 (2), 215-237, 2019 | 64 | 2019 |
| Predictors and management of loss of response to vedolizumab in inflammatory bowel disease E Shmidt, G Kochhar, J Hartke, P Chilukuri, J Meserve, K Chaudrey, ... Inflammatory bowel diseases 24 (11), 2461-2467, 2018 | 63 | 2018 |
| Can a validated sleep apnea scoring system predict cardiopulmonary events using propofol sedation for routine EGD or colonoscopy? A prospective cohort study PP Mehta, G Kochhar, S Kalra, W Maurer, J Tetzlaff, G Singh, R Lopez, ... Gastrointestinal endoscopy 79 (3), 436-444, 2014 | 60 | 2014 |
| Development and validation of clinical scoring tool to predict outcomes of treatment with vedolizumab in patients with ulcerative colitis PS Dulai, S Singh, NV Casteele, J Meserve, A Winters, S Chablaney, ... Clinical Gastroenterology and Hepatology 18 (13), 2952-2961. e8, 2020 | 57 | 2020 |
| Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium B Shen, GS Kochhar, DT Rubin, SV Kane, U Navaneethan, CN Bernstein, ... The Lancet Gastroenterology & Hepatology 7 (1), 69-95, 2022 | 56 | 2022 |
| Shorter disease duration is associated with higher rates of response to vedolizumab in patients with Crohn’s disease but not ulcerative colitis DM Faleck, A Winters, S Chablaney, P Shashi, J Meserve, A Weiss, ... Clinical Gastroenterology and Hepatology 17 (12), 2497-2505. e1, 2019 | 55 | 2019 |
| Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease M Bohm, R Xu, Y Zhang, S Varma, M Fischer, G Kochhar, B Boland, ... Alimentary Pharmacology & Therapeutics 52 (4), 669-681, 2020 | 51 | 2020 |
| Duration and severity of primary sclerosing cholangitis is not associated with risk of neoplastic changes in the colon in patients with ulcerative colitis U Navaneethan, G Kochhar, PGK Venkatesh, B Lewis, BA Lashner, ... Gastrointestinal endoscopy 75 (5), 1045-1054. e1, 2012 | 44 | 2012 |
Bo ShenColumbia University Medical Center-New York Presbyterian HospitalVerified email at cumc.columbia.edu
